Happy Ring vs Whoop (5.0 / MG) in 2026

Happy Ring

The Happy Ring (from Happy Health Inc, Austin, Texas; CEO Dustin Freckleton, MD) is the FDA-cleared, service-gated archetype of the ring sub-cohort, and the sharpest verified-vs-claimed counterpoint to RingConn: the same finger-ring form factor and similar sleep-apnea capability claims, but a diametrically opposite verification posture. Its cleared sleep-apnea algorithm is the regulatory substance, with two dated FDA 510(k) clearances: K240236 (October 8, 2024) for retrospective remote monitoring of physiological parameters in adults at home or in healthcare facilities; and K242224 (June 18, 2025) for a Home Sleep Test that processes the ring's signals for clinician-interpreted diagnosis of sleep disorders such as obstructive sleep apnea and insomnia, ages 22+, under the direction of a trained healthcare provider (clinician-directed, not autonomous diagnosis).

It is not a standalone retail ring: it is sold only bundled into the clinician-reviewed, insurer-billed 'Happy Sleep' home-sleep-test service, so there is no published consumer price. Cap-flags: a 97% agreement with polysomnography is company-reported with no peer-reviewed citation; the 'brain biometrics' marketing is not substantiated by any named EEG hardware; and funding is a $60M Series A (August 2022, ARCH Venture Partners) with no later round surfaced, an early-stage state.

Whoop (5.0 / MG)

Whoop (the 5.0 and the 'Medical Grade' MG, both launched May 8, 2025, from Whoop, founded 2012 in Boston by Will Ahmed) is a screen-free biometric wrist band and the subscription-only archetype of the biometric cohort: there is no standalone hardware sale. Access is a membership, Whoop One at $199/year, Peak at $239/year, and Life at $359/year (which includes the MG hardware), with the band provided inside the subscription.

Its PPG, skin-temperature, SpO2, and respiratory sensors feed Strain, Recovery, and Sleep Coach analytics and an LLM 'Whoop Coach'; the MG adds ECG, Blood Pressure Insights, and a Healthspan / 'Whoop Age' feature. DEPLOY records commercial maturity and a reported $10.1 billion valuation (March 2026).

Whoop is the strongest verified-vs-claimed cautionary exemplar in the cohort: its ECG is FDA-cleared (2025), but it marketed Blood Pressure Insights without clearance, drew an FDA Warning Letter on July 14, 2025, refused to remove the feature, and as of May 2026 the matter is unresolved with a class action filed, the market-first contrast to Oura's study-first posture.